Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
11 May 2012 | By GlaxoSmithKline
The FDA has approved the New Drug Application for Fabior (tazarotene) Foam...
List view / Grid view
News
Cisbio Bioassays adds three cellular kinase assays to its kinase screening platform
10 May 2012 | By Ballou PR
Company combines expertise in assay design with its powerful HTRF® technology...
New data among 200 Lucentis® abstracts at ARVO
10 May 2012 | By Novartis
Research on Lucentis® is highlighted in more than 200 abstracts this week at the 2012 ARVO annual meeting....
Webcast of Pfizer discussion at healthcare conference
10 May 2012 | By Pfizer
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with David Simmons...
FDA Advisory Committee supports approval of Gilead’s Truvada® for reducing the risk of acquiring HIV
10 May 2012 | By Gilead Sciences
Vote to support approval of once-daily oral Truvada®...
Bristol-Myers Squibb to present at Bank of America Merrill Lynch Health Care Conference
10 May 2012 | By Bristol-Myers Squibb Company
Doug Manion to will make a formal presentation...
Patheon transformation continues with adjustments to its global platform
9 May 2012 | By Patheon
Patheon continues to implement its corporate transformation strategy across its commercial and pharmaceutical development services...
BASF acquires global leader in omega-3 fatty acids for the pharmaceutical industry
9 May 2012 | By BASF
BASF has announced the acquisition of Equateq Ltd...
GSK to commence tender offer to acquire Human Genome Sciences for US $13.00 per share in cash
9 May 2012 | By GlaxoSmithKline
GSK will not participate in Human Genome Sciences strategic alternatives...
US and EU regulatory authorities accept oral BG-12 marketing applications for review
9 May 2012 | By Biogen Idec
U.S. and EU regulatory authorities have accepted marketing applications for review...
FDA Arthritis Advisory Committee recommends approval of Tofacitinib
9 May 2012 | By Pfizer
“We are pleased with the Committee’s positive evaluation..."
Customers celebrate the launch of Tecan Australia
8 May 2012 | By kdm communications limited
Tecan recently invited customers from around Australasia to mark the inauguration of Tecan Australia as a fully owned Tecan subsidiary...
New data presented at the 2012 Annual Meeting of the APA
8 May 2012 | By H. Lundbeck A/S
Lu AA21004 may have positive effect on cognitive dysfunction in patients with major depressive disorders...
Gilead Sciences to present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16
8 May 2012 | By Gilead Sciences
Webcast available through Gilead Corporate website...
Results of clinical phase III study of once-monthly aripiprazole IM depot formulation for the treatment of schizophrenia presented at APA
7 May 2012 | By H. Lundbeck A/S
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced results from a clinical phase III clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia. Trial results were presented in four poster presentations at…
